Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -35.03% is 37% above its 5-year average of -55.84%, around the middle of its 5-year range (-106.72%–32.42%).
168.53% below its 12-month average of -13.04%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.25%.
RETURN ON ASSETS (ROA)
-35.03%
RETURN ON ASSETS (ROA) AVG TTM
-13.04%
RETURN ON ASSETS (ROA) AVG 3Y
-43.14%
RETURN ON ASSETS (ROA) AVG 5Y
-55.84%
RETURN ON ASSETS (ROA) AVG 10Y
-41.34%
RETURN ON ASSETS (ROA) AVG 15Y
-54.94%
RETURN ON ASSETS (ROA) AVG 20Y
-72.39%
CURRENT VS TTM AVG
-168.53%
CURRENT VS 3Y AVG
+18.81%
CURRENT VS 5Y AVG
+37.26%
CURRENT VS 10Y AVG
+15.27%
CURRENT VS 15Y AVG
+36.24%
CURRENT VS 20Y AVG
+51.61%
SECTOR MEDIAN · HEALTHCARE
-30.18%
median of 674 covered companies
CURRENT VS SECTOR MEDIAN
-16.05%
vs the sector median at left
Abeona Therapeutics Inc.
Market Cap
$289.25M
Return on Assets (ROA)
-35.03%
TTM Avg
-13.04%
3Y Avg
-43.14%
5Y Avg
-55.84%
Market Cap
$283.44M
Return on Assets (ROA)
-26.24%
TTM Avg
-12.09%
3Y Avg
-27.60%
5Y Avg
-33.24%
Market Cap
$282.54M
Return on Assets (ROA)
-128.66%
TTM Avg
-214.31%
3Y Avg
-145.75%
5Y Avg
-133.94%
Market Cap
$292.50M
Return on Assets (ROA)
-13.93%
TTM Avg
-17.93%
3Y Avg
-26.92%
5Y Avg
-24.25%
Market Cap
$293.66M
Return on Assets (ROA)
-104.42%
TTM Avg
-76.93%
3Y Avg
-55.08%
5Y Avg
-54.19%
Market Cap
$297.60M
Return on Assets (ROA)
-48.34%
TTM Avg
-34.05%
3Y Avg
-4876.46%
5Y Avg
-3907.18%
Market Cap
$279.60M
Return on Assets (ROA)
-48.44%
TTM Avg
-42.51%
3Y Avg
-39.18%
5Y Avg
-34.60%
Market Cap
$281.22M
Return on Assets (ROA)
-18.18%
TTM Avg
-10.00%
3Y Avg
-29.10%
5Y Avg
-54.94%
Market Cap
$272.90M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abeona Therapeutics Inc. (ABEO) | $289.25M | -35.03% | -13.04% | -43.14% | -55.84% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.44M | -26.24% | -12.09% | -27.60% | -33.24% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $282.54M | -128.66% | -214.31% | -145.75% | -133.94% |
| Standard BioTools Inc. (LAB)vs › | $292.50M | -13.93% | -17.93% | -26.92% | -24.25% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $293.66M | -104.42% | -76.93% | -55.08% | -54.19% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $297.60M | -48.34% | -34.05% | -4876.46% | -3907.18% |
| Fate Therapeutics, Inc. (FATE)vs › | $279.60M | -48.44% | -42.51% | -39.18% | -34.60% |
| Aurora Cannabis Inc. (ACB)vs › | $281.22M | -18.18% | -10.00% | -29.10% | -54.94% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $272.90M | -134.38% | -47.50% | -42.91% | -40.55% |
| Benitec Biopharma Inc. (BNTC)vs › | $306.23M | -24.94% | -31.51% | -135.72% | -152.11% |
ROA
-35.0%
ROE
-49.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 32.42% |
| 2024-12-31 | -58.51% |
| 2023-12-31 | -84.67% |
| 2022-12-31 | -61.82% |
| 2021-12-31 | -106.72% |
| 2020-12-31 | -55.71% |
| 2019-12-31 | -34.15% |
| 2018-12-31 | -32.50% |
| 2017-12-31 | -15.28% |
| 2016-12-31 | -19.70% |
| 2015-12-31 | -18.15% |
| 2014-12-31 | -161.49% |
| 2013-12-31 | 725.77% |
| 2012-12-31 | -608.79% |
| 2011-12-31 | -66.90% |
| 2010-12-31 | -85.93% |
| 2009-12-31 | -1095.39% |
| 2008-12-31 | -753.56% |
| 2007-12-31 | -237.67% |
| 2006-12-31 | -200.34% |
| 2005-12-31 | -23.57% |
| 2004-12-31 | -92.32% |
| 2003-12-31 | -58.72% |
| 2002-12-31 | -48.16% |
| 2001-12-31 | -23.65% |
| 2000-12-31 | -17.78% |
| 1999-12-31 | -71.91% |
| 1998-12-31 | -141.67% |
| 1997-12-31 | -306.91% |
| 1996-12-31 | -232.59% |
